Korro Bio raises ~$70M in PIPE led by Deep Track Capital; pro-forma cash ~$236M

Korro Bio, Inc.

PIPE of 1,249,283 shares at $56.00 each for gross proceeds of ~$70M.
Pro-forma cash and equivalents ~$236M, including existing $166.4M as of 12/31/23.
Lead investor Deep Track Capital; participants include Atlas, Blue Owl, NEA, Rock Springs, Tri Locum.
Proceeds to fund Phase 1/2 trial of KRRO-110 in AATD, expected completion in 2026.
Regulatory filing for first-in-human study of KRRO-110 anticipated H2 2024; interim readout H2 2025.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Korro Bio, Inc. entered into Subscription Agreement with a number of institutional accredited investors valued at approximately $70.0 million (effective 2024-04-17).

Action: entry
Agreement: equity purchase
Counterparty: a number of institutional accredited investors
Value: approximately $70.0 million
Effective: 2024-04-17

Exact text from the filing

On April 17, 2024, we entered into a subscription agreement with a number of institutional accredited investors pursuant to which we agreed to sell and issue in a private placement

View on SEC.gov

336 material agreements filed in the last 30 days. Browse all material agreements →

Korro Bio, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-100069

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.